The call for innovation in cancer treatment has reached a critical juncture.

This has created hope and immediacy for a statement from Dr. Vishal Rao, Director, Head and Neck Surgical Oncology and Robotic Surgery at HCG Cancer Centre: “The next drug discovery story for cancer has to be from India, using data from and for Indian patients.” His vision at the Bengaluru Tech Summit resonated—not only as a beacon of possibility but also as a rallying cry for disruption in the traditional ecosystem for cancer care.

A Nation on Brink of Breakthroughs

A combination of several factors creates an opportunity for India to emerge as a global hub for innovative cancer treatments:

Diverse Data from Patients: More than 14 lakh new cancer cases are diagnosed every year; the vast and varied population in India can, therefore, provide a treasure trove of data. In fact, diversity in data is said to be the critical asset in the understanding of cancer heterogeneity and the development of precision therapies.

Talent and Innovation: The research ecosystem in India boasts some of the brightest brains in the area of oncology, pharmacology, and biotechnology. Dr. Rao himself stands tall, having three patented cancer drugs, including an allo-polyherbal formulation, to his name.

Support by Government: It is pretty much government support for an ecosystem to foster a relationship with innovation through funding and policy support, including the very recently held ‘Bengaluru Tech Summit’.

Moving Beyond ‘Carpet Bombing’

For decades, chemotherapy was the mainstay of cancer treatment—a sort of carpet bombing that hits both diseased and healthy cells. Today, the paradigm is shifting toward precision medicine, targeting cancer cells with pinpoint accuracy.

“We are moving to precision targets in cancer treatment. The era for ‘carpet bombing’ is over,” Dr. Rao added. This evolution helps not only in enhancing efficacy alone but also in reducing the considerable physical and emotional toll it takes on the patients.

While these form part of therapeutic advancement, CAR-T cell therapy, cytokine therapy, and targeted protein therapies hold the key toward personalized care. Committed to a vow of innovation by India, these approaches may bring about revolutionary changes in patients globally.

Collaborative Synergy: The Way Forward

The fight against cancer is multidisciplinary. As shared during the panel discussion at the summit, synergy among researchers, startups, clinical experts, and regulatory bodies is required. This collaboration could smooth the transition from laboratory findings to bedside treatment.

Key Areas of Collaboration

Next-Gen Immunotherapies: Advanced cancer vaccinations, dendritic cell treatment, and DNA-based vaccines hold immense promise. This looks ahead to therapies that engage a patient’s own immune system in search and destroy missions for enemy cells.

AI-Powered Drug Development: Artificial intelligence is going to blow the doors off drug discovery, accelerating data analysis, identifying potential targets, and even predicting regulatory challenges. With any luck, AI models could help researchers anticipate FDA rejections and save precious time and resources.

Combinatory Approach: Targeted therapies combined with a “pan approach” may avoid the tendency of cancer cells to become resistant to one type of therapy. As already pointed out by Dr. Jyothsna Rao, these combinations are going to work in a synergistic manner—so that the therapies do not just work today but for years to come.

Overcoming Challenges

Yet, as immense as the opportunities are, several challenges mark the road to the discovery of a breakthrough drug in cancer:

  • Heterogeneity of Cancer Cells: In fact, by their very nature, cancer cells remain an elusive target. According to Dr. Jyothsna Rao, targeting a single molecule usually results in resistance and relapse.
  • Regulatory Challenges: Drug approval has to overcome a long, cumbersome path of data collation, clinical trials, and conformity to very high standards.
  • Resource Allocation: In as much as the government may be supportive, huge investment in infrastructure, talent, and technology is needed to keep innovation running.

A Call to Action

These challenges also present an opportunity for India to lead the next wave of cancer innovation, building on its unique strengths. According to a vision outlined by Dr. Rao, the following is key:

  • Invest in Research: There is a dire need for increased funding in oncology research, especially in new areas like immunotherapy and precision medicine.
  • Leveraging AI and Technology: AI is one of the tools that could democratize access to state-of-the-art treatments and develop drugs in a much more efficient way.
  • Fostering Collaboration: Breaking silos between academia, industry, and government can accelerate progress.

Inspiration for Budding Innovators

Dr. Rao’s story stands out as one of both perseverance and innovation. The ability to patent three cancer drugs, one among them being an allo-polyherbal therapy, shows the extent to which determination and ingenuity can take one.

The call of his story to youngsters, researchers, and entrepreneurs, therefore, goes: “Believe in your ideas, question the status quo, and build towards a cause much larger than yourself.”

The Motivation to Dream Big

India’s quest to develop the next cancer drug is more than a scientific pursuit—it’s a national mission. It reflects the spirit of resilience, determination, and innovation that defines the country. The story of cancer research in India is one of hope: hope for patients, for families, and for a world free from the scourge of cancer. To borrow the words of Dr. Rao so aptly, “That has to change.” These four words bring into focus a bright vision of the future, a commitment to address unmet needs for millions, and a determination that no patient is left without options on day one.

The Way Forward

India stands at the threshold of a healthcare revolution. Intellectual capital, diverse patient data, and a spirit of collaboration can help the country rise as a global leader in cancer innovation.

The next chapter in cancer treatment could be written from the laboratories and clinics of India. Not a possibility, but an absolute necessity, for every patient, researcher, and healthcare professional, let us rise to make it happen. The world is waiting.

Dr. Prahlada N.B
MBBS (JJMMC), MS (PGIMER, Chandigarh). 
MBA (BITS, Pilani), MHA, 
Executive Programme in Strategic Management (IIM, Lucknow)
Senior Management Programme in Healthcare Management (IIM, Kozhikode)
Postgraduate Certificate in Technology Leadership and Innovation (MIT, USA)
Advanced Certificate in AI for Digital Health and Imaging Program (IISc, Bengaluru). 

Senior Professor and former Head, 
Department of ENT-Head & Neck Surgery, Skull Base Surgery, Cochlear Implant Surgery. 
Basaveshwara Medical College & Hospital, Chitradurga, Karnataka, India. 

My Vision: I don’t want to be a genius.  I want to be a person with a bundle of experience. 

My Mission: Help others achieve their life’s objectives in my presence or absence!

My Values:  Creating value for others. 

Leave a reply